Key Laboratory of New Animal Drug Project, Gansu Province/Key Laboratory of Veterinary Pharmaceutical Development, Ministry of Agriculture and Rural Affairs/Lanzhou Institute of Husbandry and Pharmaceutical Sciences of CAAS, Lanzhou 730050, China.
Shandong Provincial Animal and Poultry Green Health Products Creation Engineering Laboratory, Institute of Poultry Science, Shandong Academy of Agricultural Science, Jinan 250023, China.
Int J Mol Sci. 2023 Sep 29;24(19):14729. doi: 10.3390/ijms241914729.
To investigate the effect of polymer blends on the in vitro release/degradation and pharmacokinetics of moxidectin-loaded PLGA microspheres (MOX-MS), four formulations (F1, F2, F3 and F4) were prepared using the O/W emulsion solvent evaporation method by blending high (75/25, 75 kDa) and low (50/50, 23 kDa) molecular weight PLGA with different ratios. The addition of low-molecular-weight PLGA did not change the release mechanism of microspheres, but sped up the drug release of microspheres and drastically shortened the lag phase. The in vitro degradation results show that the release of microspheres consisted of a combination of pore diffusion and erosion, and especially autocatalysis played an important role in this process. Furthermore, an accelerated release method was also developed to reduce the period for drug release testing within one month. The pharmacokinetic results demonstrated that MOX-MS could be released for at least 60 days with only a slight blood drug concentration fluctuation. In particular, F3 displayed the highest AUC and plasma concentration (AUC = 596.53 ng/mL·d, C = 8.84 ng/mL), making it the optimal formulation. Overall, these results indicate that using polymer blends could easily adjust hydrophobic drug release from microspheres and notably reduce the lag phase of microspheres.
为了研究聚合物共混物对载有莫昔克丁的 PLGA 微球(MOX-MS)的体外释放/降解和药代动力学的影响,使用 O/W 乳液溶剂蒸发法通过共混具有不同比例的高分子量(75/25,75 kDa)和低分子量(50/50,23 kDa)PLGA 制备了四种制剂(F1、F2、F3 和 F4)。添加低分子量 PLGA 不会改变微球的释放机制,但会加速微球的药物释放,并大大缩短滞后期。体外降解结果表明,微球的释放由孔扩散和侵蚀的组合组成,特别是自催化在该过程中起重要作用。此外,还开发了一种加速释放方法,以将药物释放测试的周期缩短至一个月内。药代动力学结果表明,MOX-MS 可以至少释放 60 天,而血药浓度波动很小。特别是 F3 显示出最高的 AUC 和血浆浓度(AUC=596.53ng/mL·d,C=8.84ng/mL),使其成为最佳制剂。总体而言,这些结果表明,使用聚合物共混物可以轻松调整疏水性药物从微球中的释放,并显著缩短微球的滞后期。